COMMUNIQUÉS West-GlobeNewswire

Becoming Independent Named No. 17 on “The NonProfit Times' 2026 Best Nonprofits To Work For”
21/04/2026
Santa Rosa Nonprofit Earns National Recognition for Exceptional Workplace Culture and Employee Experience SANTA ROSA, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Becoming Independent , a nonprofit supporting adults with [...]
Remix Therapeutics Announces Oral Presentation of First-in-Class Small Molecule MYB mRNA Degrader REM-422 Phase 1/2 ARIA Trial Results at the 2026 American Society of Clinical Oncology Annual Meeting
21/04/2026
Results of Phase 1 Dose-Escalation Cohort Including Antitumor Activity and Safety of REM-422 in Adenoid Cystic Carcinoma WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage [...]
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
21/04/2026
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Eclipse Energy and Wood to Scale Hydrogen Production from End-of-Life Oil Fields
21/04/2026
Strategic collaboration positions Wood as a preferred engineering partner as Eclipse moves its reservoir-to-hydrogen technology toward global project development HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- As demand [...]
Le Gala de la Fondation de l’Hôpital de Lachine recueille 322 115 $ pour transformer les soins de santé dans l’Ouest-de-l’Île
21/04/2026
DORVAL, Québec, 21 avr. 2026 (GLOBE NEWSWIRE) -- Le Gala de la Fondation de l’Hôpital de Lachine a permis de recueillir 322 115 $. Cette somme servira à soutenir la campagne Osez rêver : Hôpital de Lachine , un [...]
Lachine Hospital Foundation Gala raises $322,115 to transform health care in the West Island
21/04/2026
DORVAL, Quebec, April 21, 2026 (GLOBE NEWSWIRE) -- The Lachine Hospital Foundation’s signature gala raised $322,115 in support of the Dream Big: Lachine Hospital campaign—a powerful collaboration with the MUHC [...]
Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment
21/04/2026
Data demonstrates strong and higher secondary patency compared to conventional arteriovenous grafts (AVG) to meaningfully transform vascular access 79% secondary patency at 12 months in complex patient populations [...]
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies
21/04/2026
NANJING, China, April 21, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the first patient has been successfully dosed in a phase Ⅱ [...]
ImPact Biotech Announces Upcoming Data Presentations for Padeliporfin VTP at AUA and ASCO 2026
21/04/2026
– Company to present updated data from the Phase 3 ENLIGHTED trial of Pa deliporfin VTP in LG UTUC with topline data expected in 2026 – – Additional preliminary data from the Phase 1 trial in LA-PDAC to be presented at [...]
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
21/04/2026
To Highlight Efficacy Results from Relapsed or Refractory Waldenström Macroglobulinemia Patients Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy FLORHAM PARK, N.J., April 21, 2026 (GLOBE [...]
ACTG Launches Critical Study Evaluating Hormone Therapy for Women Living with HIV in the Menopause Transition
21/04/2026
CHAPEL HILL, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the HoT study (Menopausal Hormone Therapy for [...]
Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting
21/04/2026
WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
21/04/2026
SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced it will present [...]
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
21/04/2026
Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the randomized Phase 2 trial of silevertinib in patients with newly diagnosed [...]
GLP Diet App Launches Personalized Wellness App for GLP-1 Medication Users, Earns 2,500+ App Reviews
21/04/2026
Inside the App GLP-1 Users Are Calling a Game-Changer – Reviews, Features, and What Sets It Apart NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- GLP Diet App has launched a dedicated wellness app designed to support [...]
ITM to Announce Quality of Life Data from the Phase 3 COMPETE Trial in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at ASCO 2026
21/04/2026
Garching / Munich, April 21 , 2026 –– ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today announced that it will provide quality of life data from its Phase 3 COMPETE trial in [...]
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
21/04/2026
As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG U.S. regulatory application [...]
Trethera Announces Appointment of M. Andrew (“Drew”) Woodmansee to Board of Directors
21/04/2026
LOS ANGELES, April 21, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company developing first-in-class therapies for cancer, autoimmune, and neuroimmune diseases, today [...]
Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026
21/04/2026
ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial [...]

Pages